Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation

Eur Radiol. 2013 Mar;23(3):805-15. doi: 10.1007/s00330-012-2646-4. Epub 2012 Sep 22.

Abstract

Objective: To evaluate morphological and perfusion changes in liver metastases of neuroendocrine tumours by contrast-enhanced ultrasound (CEUS) after transarterial embolisation with bead block (TAE) or trans-arterial chemoembolisation with doxorubicin-eluting beads (DEB-TACE).

Methods: In this retrospective study, seven patients underwent TAE, and ten underwent DEB-TACE using beads of the same size. At 1 day before embolisation, 2 days, 1 month and 3 months after the procedure, a destruction-replenishment study using CEUS was performed with a microbubble-enhancing contrast material on a reference tumour. Relative blood flow (rBF) and relative blood volume (rBV) were obtained from the ratio of values obtained in the tumour and in adjacent liver parenchyma. Morphological parameters such as the tumour's major diameter and the viable tumour's major diameter were also measured. A parameter combining functional and morphological data, the tumour vitality index (TVI), was studied. The Wilcoxon rank-sum test and Fisher's test were used to compare treatment groups.

Results: At 3 months rBF, rBV and TVI were significantly lower (P = 0.005, P = 0.04 and P = 0.03) for the group with doxorubicin. No difference in morphological parameters was found throughout the follow-up.

Conclusions: One parameter, TVI, could evaluate the morphological and functional response to treatments.

MeSH terms

  • Aged
  • Contrast Media
  • Embolization, Therapeutic / methods*
  • Female
  • Humans
  • Liver Neoplasms / diagnostic imaging*
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / therapy*
  • Neuroendocrine Tumors / diagnostic imaging*
  • Neuroendocrine Tumors / secondary*
  • Neuroendocrine Tumors / therapy
  • Phospholipids
  • Retrospective Studies
  • Sulfur Hexafluoride
  • Treatment Outcome
  • Ultrasonography / methods*

Substances

  • Contrast Media
  • Phospholipids
  • contrast agent BR1
  • Sulfur Hexafluoride